Rubina Munir1, Muhammad Zia-Ur-Rehman2, Shahzad Murtaza3, Sumera Zaib4, Noman Javid1,5, Sana Javaid Awan6,7, Kiran Iftikhar3, Muhammad Makshoof Athar1, Imtiaz Khan8. 1. Institute of Chemistry, University of the Punjab, Lahore 54590, Pakistan. 2. Applied Chemistry Research Centre, PCSIR Laboratories Complex, Lahore 54600, Pakistan. 3. Department of Chemistry, University of Gujrat, Gujrat 50700, Pakistan. 4. Department of Biochemistry, Faculty of Life Sciences, University of Central Punjab, Lahore 54590, Pakistan. 5. Department of Chemistry (C-Block), Forman Christian College, Ferozepur Road, Lahore 54600, Pakistan. 6. Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan. 7. Department of Zoology, Kinnaird College for Women, Lahore 54000, Pakistan. 8. Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Abstract
Alzheimer's disease (AD), a progressive neurodegenerative disorder, characterized by central cognitive dysfunction, memory loss, and intellectual decline poses a major public health problem affecting millions of people around the globe. Despite several clinically approved drugs and development of anti-Alzheimer's heterocyclic structural leads, the treatment of AD requires safer hybrid therapeutics with characteristic structural and biochemical properties. In this endeavor, we herein report a microwave-assisted synthesis of a library of quinoline thiosemicarbazones endowed with a piperidine moiety, achieved via the condensation of 6/8-methyl-2-(piperidin-1-yl)quinoline-3-carbaldehydes and (un)substituted thiosemicarbazides. The target N-heterocyclic products were isolated in excellent yields. The structures of all the synthesized compounds were fully established using readily available spectroscopic techniques (FTIR, 1H- and 13C-NMR). Anti-Alzheimer potential of the synthesized heterocyclic compounds was evaluated using acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. The in vitro biochemical assay results revealed several compounds as potent inhibitors of both enzymes. Among them, five compounds exhibited IC50 values less than 20 μM. N-(3-chlorophenyl)-2-((8-methyl-2-(piperidin-1-yl)quinolin-3-yl)methylene)hydrazine carbothioamide emerged as the most potent dual inhibitor of AChE and BChE with IC50 values of 9.68 and 11.59 μM, respectively. Various informative structure-activity relationship (SAR) analyses were also concluded indicating the critical role of substitution pattern on the inhibitory efficacy of the tested derivatives. In vitro results were further validated through molecular docking analysis where interactive behavior of the potent inhibitors within the active pocket of enzymes was established. Quinoline thiosemicarbazones were also tested for their cytotoxicity using MTT assay against HepG2 cells. Among the 26 novel compounds, there were five cytotoxical and 18 showed proliferative properties.
Alzheimer's disease (n class="Disease">AD), a progressive neurodegenerative disorder, characterized by central cognitive dysfunction, memory loss, and intellectual decline poses a major public health problem affecting millions of peoplearound the globe. Despite several clinically approved drugs and development of anti-Alzheimer's heterocyclic structural leads, the treatment of AD requires safer hybrid therapeutics with characteristic structural and biochemical properties. In this endeavor, we herein report a microwave-assisted synthesis of a library of quinoline thiosemicarbazones endowed with a piperidine moiety, achieved via the condensation of 6/8-methyl-2-(piperidin-1-yl)quinoline-3-carbaldehydes and (un)substituted thiosemicarbazides. The target N-heterocyclic products were isolated in excellent yields. The structures of all the synthesized compounds were fully established using readily available spectroscopic techniques (FTIR, 1H- and 13C-NMR). Anti-Alzheimer potential of the synthesized heterocyclic compounds was evaluated using acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. The in vitro biochemical assay results revealed several compounds as potent inhibitors of both enzymes. Among them, five compounds exhibited IC50 values less than 20 μM. N-(3-chlorophenyl)-2-((8-methyl-2-(piperidin-1-yl)quinolin-3-yl)methylene)hydrazine carbothioamide emerged as the most potent dual inhibitor of AChE and BChE with IC50 values of 9.68 and 11.59 μM, respectively. Various informative structure-activity relationship (SAR) analyses were also concluded indicating the critical role of substitution pattern on the inhibitory efficacy of the tested derivatives. In vitro results were further validated through molecular docking analysis where interactive behavior of the potent inhibitors within the active pocket of enzymes was established. Quinoline thiosemicarbazones were also tested for their cytotoxicity using MTT assay against HepG2 cells. Among the 26 novel compounds, there were five cytotoxical and 18 showed proliferative properties.
Authors: Maniyan Padmanilayam; Bernard Scorneaux; Yuxiang Dong; Jacques Chollet; Hugues Matile; Susan A Charman; Darren J Creek; William N Charman; Josefina Santo Tomas; Christian Scheurer; Sergio Wittlin; Reto Brun; Jonathan L Vennerstrom Journal: Bioorg Med Chem Lett Date: 2006-08-22 Impact factor: 2.823
Authors: Duraippandi Palanimuthu; Rachal Poon; Sumit Sahni; Rukhsana Anjum; David Hibbs; Hsuan-Yu Lin; Paul V Bernhardt; Danuta S Kalinowski; Des R Richardson Journal: Eur J Med Chem Date: 2017-08-09 Impact factor: 6.514
Authors: E Rajanarendar; M Nagi Reddy; S Rama Krishna; K Rama Murthy; Y N Reddy; M V Rajam Journal: Eur J Med Chem Date: 2012-07-24 Impact factor: 6.514
Authors: Priyabrata Das; Xiaoyi Deng; Liang Zhang; Michael G Roth; Beatriz M A Fontoura; Margaret A Phillips; Jef K De Brabander Journal: ACS Med Chem Lett Date: 2013-06-13 Impact factor: 4.345
Authors: Furqan Ahmad Saddique; Sana Aslam; Matloob Ahmad; Usman Ali Ashfaq; Muhammad Muddassar; Sadia Sultan; Saman Taj; Muzammil Hussain; Dae Sung Lee; Magdi E A Zaki Journal: Molecules Date: 2021-05-20 Impact factor: 4.411
Authors: Furqan Ahmad Saddique; Matloob Ahmad; Usman Ali Ashfaq; Muhammad Muddassar; Sadia Sultan; Magdi E A Zaki Journal: Pharmaceuticals (Basel) Date: 2022-01-17